BioGenex, a pioneer in automated in situ hybridization systems, is pleased to announce the launch of 235 fully optimized microRNA (miRNA) probe kits, that provide a complete solution for in situ hybridization experiments with clean and accurate results. BioGenex miRNA probes are selected for brain, kidney, gastric, lung, cervical, prostate, breast, and pancreatic cancer panels. Each panel is presented with initial validation for various applications including CUP, undifferentiated and poorly differentiated tumors, and grading and scoring of tumor lesions.
BioGenex is now accepting proposals for Precision Medicine Research, using miRNA ISH, and offering grants of over $500,000. Grant recipients may receive BioGenex miRNA probes and detection reagents, and/or a family of Xmatrx® automated systems (Xmatrx® Infinity, NANO, and MINI) with technical support based on proposals. Please apply below!